open access

Vol 90, No 8 (2019)
REVIEW PAPERS Obstetrics
Published online: 2019-08-30
Get Citation

Evaluation of asthma course in pregnancy

Agnieszka Rey, Ewa Jassem, Marta Chelminska
DOI: 10.5603/GP.2019.0080
·
Pubmed: 31482550
·
Ginekol Pol 2019;90(8):464-469.

open access

Vol 90, No 8 (2019)
REVIEW PAPERS Obstetrics
Published online: 2019-08-30

Abstract

The prevalence of asthma has been rising in recent decades. It is the most common disease among pregnant women and affects ca. 12% of this population. The course of asthma in pregnancy may change. In 1/3 of patients, it worsens; in 1/3 of patients, the symptoms are milder; in 1/3 of patients, it remains unchanged. Well-controlled asthma decreases the risk of pregnancy complications. Uncontrolled and severe asthma increases the risk of congenital malformations and obstetrical complications for both mother and baby. Exacerbations may also contribute to poor pregnancy outcomes. These occur mostly either in the first or in the second trimester. The most common triggers are viral infections and treatment non-compliance. The key to maintaining and gaining control of asthma is active treatment of asthma and its exacerbations.

Abstract

The prevalence of asthma has been rising in recent decades. It is the most common disease among pregnant women and affects ca. 12% of this population. The course of asthma in pregnancy may change. In 1/3 of patients, it worsens; in 1/3 of patients, the symptoms are milder; in 1/3 of patients, it remains unchanged. Well-controlled asthma decreases the risk of pregnancy complications. Uncontrolled and severe asthma increases the risk of congenital malformations and obstetrical complications for both mother and baby. Exacerbations may also contribute to poor pregnancy outcomes. These occur mostly either in the first or in the second trimester. The most common triggers are viral infections and treatment non-compliance. The key to maintaining and gaining control of asthma is active treatment of asthma and its exacerbations.

Get Citation

Keywords

asthma; pregnancy; asthma exacerbations; asthma treatment; asthma diagnosis

About this article
Title

Evaluation of asthma course in pregnancy

Journal

Ginekologia Polska

Issue

Vol 90, No 8 (2019)

Pages

464-469

Published online

2019-08-30

DOI

10.5603/GP.2019.0080

Pubmed

31482550

Bibliographic record

Ginekol Pol 2019;90(8):464-469.

Keywords

asthma
pregnancy
asthma exacerbations
asthma treatment
asthma diagnosis

Authors

Agnieszka Rey
Ewa Jassem
Marta Chelminska

References (35)
  1. Rogala B. Astma u kobiet w ciąży. Alergologia Polska - Polish Journal of Allergology. 2015; 2(3): 94–98.
  2. Wang G, Murphy VE, Namazy J, et al. The risk of maternal and placental complications in pregnant women with asthma: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2014; 27(9): 934–942.
  3. Ali Z, Nilas L, Ulrik CS. Low risk of adverse obstetrical and perinatal outcome in pregnancies complicated by asthma: A case control study. Respir Med. 2016; 120: 124–130.
  4. Kelly W, Massoumi A, Lazarus A. Asthma in pregnancy: Physiology, diagnosis, and management. Postgrad Med. 2015; 127(4): 349–358.
  5. Fal A. Alergia, choroby alergiczne, astma [Allergy, allergic diseases, asthma]. MP, Kraków 2010: 423–430.
  6. Robijn AL, Murphy VE, Gibson PG, et al. Asthma in pregnancy. Clin Chest Med. 2011; 32(1): 93–110.
  7. Tamási L, Horváth I, Bohács A, et al. Asthma in pregnancy – Immunological changes and clinical management. Respiratory Medicine. 2011; 105(2): 159–164.
  8. Minerbi-Codish I, Fraser D, Avnun L, et al. Influence of asthma in pregnancy on labor and the newborn. Respiration. 1998; 65(2): 130–135.
  9. Murphy VE, Clifton VL, Gibson PG. Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. Thorax. 2006; 61(2): 169–176.
  10. Garne E, Hansen AV, Morris J, et al. Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study. J Allergy Clin Immunol. 2015; 136(6): 1496–1502.e7.
  11. Murphy VE, Wang G, Namazy JA, et al. A meta-analysis of adverse perinatal outcomes in women with asthma. BJOG. 2011; 118(11): 1314–1323.
  12. Morten M, Collison A, Murphy VE, et al. Managing asthma in pregnancy. Breathe (Sheff). 2015; 11(4): 258–267.
  13. Global Initiative for Asthma. www.ginasthma.com (20.03.2019).
  14. Cooper BG, Cooper BG. An update on contraindications for lung function testing. Thorax. 2011; 66(8): 714–723.
  15. Zairina E, Abramson MJ, McDonald CF, et al. A prospective cohort study of pulmonary function during pregnancy in women with and without asthma. J Asthma. 2016; 53(2): 155–163.
  16. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011; 378(9795): 983–990.
  17. Eltonsy S, Kettani FZ, Blais L. Beta2-agonists use during pregnancy and perinatal outcomes: a systematic review. Respir Med. 2014; 108(1): 9–33.
  18. Eltonsy S, Forget A, Beauchesne MF, et al. Risk of congenital malformations for asthmatic pregnant women using a long-acting β₂-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy. J Allergy Clin Immunol. 2015; 135(1): 123–130.
  19. Blais L, Beauchesne MF, Lemière C, et al. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. J Allergy Clin Immunol. 2009; 124(6): 1229–1234.e4.
  20. Gregersen TL, Ulrik CS. Safety of bronchodilators and corticosteroids for asthma during pregnancy: what we know and what we need to do better. J Asthma Allergy. 2013; 6: 117–125.
  21. Bakhireva LN, Jones KL, Schatz M, et al. Organization of Teratology Information Specialists Collaborative Research Group. Safety of leukotriene receptor antagonists in pregnancy. J Allergy Clin Immunol. 2007; 119(3): 618–625.
  22. Namazy JA, Blais L, Andrews EB, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015; 135(2): 407–412.
  23. Zetstra-van der Woude PA, Vroegop JS, Bos HJ, et al. A population analysis of prescriptions for asthma medications during pregnancy. J Allergy Clin Immunol. 2013; 131(3): 711–717.
  24. Kuczkowski KM. Labor analgesia for the parturient with respiratory disease: what does an obstetrician need to know? Arch Gynecol Obstet. 2005; 272(2): 160–166.
  25. Lim A, Hussainy S, Abramson M. Asthma drugs in pregnancy and lactation. Australian Prescriber. 2013; 36(5): 150–153.
  26. Toxicology data network. https://toxnet.nlm.nih.gov/ (27.06.2019).
  27. Merlob P, Weber-Schöndorfer C. Antiallergics, antiasthmatics and antitussives. Drugs During Pregnancy and Lactation. 2015: 671–676.
  28. Ali Z, Nilas L, Ulrik CS. Determinants of low risk of asthma exacerbation during pregnancy. Clin Exp Allergy. 2018; 48(1): 23–28.
  29. Blais L, Kettani FZ, Forget A, et al. Asthma exacerbations during the first trimester of pregnancy and congenital malformations: revisiting the association in a large representative cohort. Thorax. 2015; 70(7): 647–652.
  30. Jain S, Kamimoto L, Bramley AM, et al. 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009; 361(20): 1935–1944.
  31. Rastogi D, Wang C, Lendor C, et al. T-helper type 2 polarization among asthmatics during and following pregnancy. Clin Exp Allergy. 2006; 36(7): 892–898.
  32. Andres RL, Day MC. Perinatal complications associated with maternal tobacco use. Semin Neonatol. 2000; 5(3): 231–241.
  33. Balwicki Ł, Zarzeczna-Baran M, Wierucki Ł, et al. Smoking among pregnant women in small towns in Poland. Int J Public Health. 2016; 61(1): 111–118.
  34. Hodyl NA, Stark MJ, Scheil W, et al. Perinatal outcomes following maternal asthma and cigarette smoking during pregnancy. Eur Respir J. 2014; 43(3): 704–716.
  35. Bidad K, Heidarnazhad H, Pourpak Z, et al. Gastroesophageal Reflux Disease and Asthma in Pregnant Women with Dyspnea. 2014; 13: 104–1099.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl